Insulin Resistance and Inflammation: The Two-Way Connection

If you have heard that inflammation is linked to type 2 diabetes or metabolic syndrome, you may have assumed the connection was indirect, perhaps something like "inflammation is bad for many things, and diabetes is one of them." The reality is considerably more specific. The biological pathways that drive chronic inflammation and those that drive insulin resistance overlap so extensively that researchers now treat them as two outputs of the same underlying dysfunction. Understanding that overlap is practically useful: it changes what you look for, what you measure, and where you focus your effort.

How Inflammation Interferes with Insulin Signaling

Insulin's job is to bind to a receptor on the cell surface and trigger a cascade of molecular events that allow glucose to move from the blood into the cell. That cascade depends on a series of phosphorylation steps inside the cell, and two of those steps are particularly vulnerable to disruption by inflammatory signals. The first involves a protein called insulin receptor substrate-1 (IRS-1). Under normal conditions, insulin binding causes IRS-1 to be phosphorylated on specific serine residues in a way that keeps the cascade moving. When pro-inflammatory cytokines such as tumor necrosis factor-alpha (TNF-alpha) and interleukin-6 (IL-6) are elevated, they activate kinases that phosphorylate IRS-1 on different serine residues, which acts more like a brake than an accelerator. The downstream signal stalls, and even though insulin is present and binding normally, glucose uptake is impaired.

A second point of interference involves a transcription factor called NF-kappa-B, which acts as a master switch for inflammatory gene expression. Under chronic inflammatory conditions, NF-kappa-B is persistently active, sustaining the production of TNF-alpha, IL-6, IL-1, and other cytokines that keep phosphorylating IRS-1 in the inhibitory pattern. This creates a self-sustaining loop within the cell: inflammation impairs the insulin signal, and the resulting metabolic dysfunction further amplifies the inflammatory state. A clinical review in Archivum Immunologiae et Therapiae Experimentalis described this interplay clearly, noting that while animal models have consistently supported a central role for NF-kappa-B and various pro-inflammatory cytokines in insulin resistance, human neutralization studies have begun to clarify which cytokines matter most in people, with IL-1 family members appearing particularly important (Wieser, Moschen, and Tilg, 2013).

How Insulin-Resistant Fat Tissue Becomes an Inflammatory Engine

The second half of the two-way connection runs in the opposite direction: insulin-resistant tissue, especially visceral adipose tissue, becomes a major producer of the very inflammatory signals that block insulin action. Normal, healthy fat cells store and release energy and produce molecules that regulate appetite and metabolism. But when fat cells expand beyond a certain size, particularly in the visceral deposits around the abdominal organs, their biology changes. They begin to secrete higher levels of pro-inflammatory cytokines and lower levels of adiponectin, a hormone with anti-inflammatory and insulin-sensitizing properties.

Tumor necrosis factor-alpha (TNF-alpha) holds a historically important place in this story. It was the first molecule described as an "adipokine," meaning a signaling molecule produced by fat tissue with systemic effects on metabolism. A comprehensive review in Nature Metabolism by Sethi and Hotamisligil traced the discovery of TNF-alpha's metabolic role, describing it as the molecule that established adipose tissue as an active immune organ rather than a passive energy store, and framing the resulting field as "immunometabolism" or "metaflammation," a form of chronic, low-grade, metabolic inflammation distinct from the acute inflammation of injury or infection (Sethi and Hotamisligil, 2021). As fat mass grows, macrophages are recruited into the adipose tissue, resident macrophages shift toward a more pro-inflammatory state, and the organ that was once largely metabolically quiet becomes a sustained source of circulating cytokines that spread the inflammatory signal throughout the body.

Elevated free fatty acids add another layer to this problem. When fat cells spill excess free fatty acids into the bloodstream, as they do in the insulin-resistant state, those fatty acids can activate toll-like receptor 4 (TLR4) on immune cells and other tissues. TLR4 is the same receptor the immune system uses to recognize bacterial cell walls, so its activation triggers a genuine inflammatory response, one that further amplifies NF-kappa-B activity and cytokine production. The result is a second self-reinforcing loop, this time operating at the tissue and systemic level rather than the individual cell level.

What CRP Shows You About This Cycle

C-reactive protein is a useful window into this process because the liver produces it in direct response to IL-6, one of the key cytokines released by inflamed adipose tissue. When visceral fat mass increases and the metaflammatory state intensifies, IL-6 levels rise, and CRP follows. Because the liver integrates signals from multiple inflammatory sources, CRP reflects the net inflammatory burden across the whole body rather than any single tissue, which is what makes it valuable as a general wellness marker.

The connection between CRP and insulin resistance holds up in population data over time. A large prospective observational study using the CARDIA cohort followed participants over a five-year period and found that higher CRP was significantly associated with worsening insulin resistance as measured by HOMA-IR, both cross-sectionally and longitudinally. Critically, the association remained statistically significant even after controlling for body fat measurements, suggesting that inflammation tracks with insulin sensitivity independently of obesity, not just as a byproduct of it (Park et al., 2009). People in the highest CRP quartile were projected to accumulate more insulin resistance over time than those in the lowest quartile, even when their body composition was similar.

Looking further down the metabolic trajectory, combining elevated CRP with markers of hyperinsulinemia identifies individuals at meaningfully higher risk. A large prospective cohort study in Diabetes Care tracked over 7,000 adults with recently diagnosed type 2 diabetes and found that high hs-CRP (above 3 mg/L) versus low hs-CRP (below 1 mg/L) was associated with a 45 percent higher risk of cardiovascular events and a 147 percent higher risk of all-cause mortality during a median follow-up of nearly five years. When high CRP was combined with high C-peptide, a marker of elevated insulin secretion and insulin resistance, the risks were even further elevated (Gedebjerg et al., 2023). CRP is a general wellness marker rather than a diagnostic test, and persistently elevated levels always warrant a conversation with a healthcare provider, but this data illustrates why tracking inflammatory status matters as part of a broader metabolic picture.

Why Visceral Fat Is the Epicenter

Not all body fat participates in this cycle equally. Subcutaneous fat, the fat stored just beneath the skin at places like the thighs and arms, is metabolically less active and contributes far less to systemic inflammation and insulin resistance. Visceral fat, the fat stored in the abdominal cavity around the liver, pancreas, and intestines, is the primary driver. Visceral fat cells are more metabolically active, more responsive to stress hormones, more prone to macrophage infiltration, and more likely to deliver their output directly to the portal circulation, meaning the liver receives an especially concentrated dose of their inflammatory signals.

This is why waist circumference can be a meaningful complement to body weight when thinking about inflammatory risk. Two people with the same BMI can have dramatically different visceral fat levels and, consequently, different levels of systemic inflammation and insulin sensitivity. Neither measure is a substitute for medical evaluation, but understanding the visceral fat story helps explain why some people with modest excess weight carry more inflammatory markers than expected, and why others with higher weight but favorable fat distribution show less metabolic disruption.

The liver also plays a central role in this picture. When the portal circulation delivers excess free fatty acids and inflammatory cytokines from visceral fat to the liver, the liver responds by becoming less sensitive to insulin itself and by producing more glucose through a process called gluconeogenesis. This hepatic insulin resistance contributes to elevated fasting blood sugar and drives the pancreas to secrete even more insulin, raising circulating insulin levels further. Elevated insulin, in turn, promotes further fat storage in the visceral depot. The cycle is complete.

Breaking the Cycle: What the Evidence Supports

The most powerful intervention for disrupting the inflammation-insulin resistance cycle is reducing visceral fat mass. Because visceral fat is the primary source of the pro-inflammatory cytokines driving the dysfunction, reducing it removes fuel from the fire at the most upstream point. Weight loss through any combination of caloric deficit and increased physical activity consistently improves both CRP and insulin sensitivity. The review by Wieser and colleagues noted that weight loss reduces the enhanced cytokine expression in adipose tissue and thereby improves systemic inflammation, and this relationship has been replicated across hundreds of clinical trials. Even modest weight loss of five to ten percent of body weight can produce meaningful reductions in visceral fat and measurable improvements in CRP and HOMA-IR.

Physical activity contributes to the cycle-breaking work through mechanisms that extend beyond weight loss alone. Exercise improves insulin sensitivity in muscle by increasing the density of glucose transporters (particularly GLUT4) and improving mitochondrial function, and these effects occur independently of changes in fat mass. Regular movement also reduces circulating cytokine levels through mechanisms that likely involve exercise-induced anti-inflammatory signaling, including the release of muscle-derived molecules called myokines that have systemic anti-inflammatory effects. The magnitude of the effect varies with the type, intensity, and duration of exercise, but consistent aerobic and resistance training both contribute.

Dietary composition matters alongside overall caloric balance. Diets high in refined carbohydrates and added sugars drive postprandial glucose and insulin spikes that, over time, contribute to beta-cell stress and worsening insulin resistance. Ultra-processed foods tend to be high in refined starches, added sugars, and industrial seed oils, all of which can promote inflammation. In contrast, dietary patterns rich in fiber, polyphenols, and anti-inflammatory fats, the hallmarks of Mediterranean-style eating, support both insulin sensitivity and lower CRP. Fiber deserves particular attention because it slows glucose absorption, supports a microbiome composition associated with lower inflammation, and directly reduces CRP in clinical trials.

Sleep quality is an underappreciated lever in this system. Short sleep duration and poor sleep quality independently worsen insulin sensitivity and elevate inflammatory markers. The mechanisms include elevated cortisol, increased sympathetic nervous system activity, and disrupted appetite hormone signaling that promotes caloric excess. People working on insulin resistance and inflammation who neglect sleep may find their dietary and exercise efforts produce smaller returns than expected.

What ties these levers together is the ability to measure the result. CRP reflects the net output of the inflammatory side of this system, and tracking it over time gives you a signal about whether the changes you are making are shifting the underlying biology. Because CRP integrates inputs from diet, activity, body composition, sleep, and stress, a downward trend in CRP is meaningful evidence that the cycle is being disrupted, not just that one marker has moved. Sustained elevations warrant discussion with a healthcare provider to rule out other causes and consider further metabolic evaluation.

Sources

• Wieser V, Moschen AR, Tilg H. Inflammation, cytokines and insulin resistance: a clinical perspective. Archivum Immunologiae et Therapiae Experimentalis, 2013. pubmed.ncbi.nlm.nih.gov/23307037
• Sethi JK, Hotamisligil GS. Metabolic Messengers: tumour necrosis factor. Nature Metabolism, 2021. pubmed.ncbi.nlm.nih.gov/34650277
• Park K, Steffes M, Lee D-H, Himes JH, Jacobs DR. Association of inflammation with worsening HOMA-insulin resistance. Diabetologia, 2009. pubmed.ncbi.nlm.nih.gov/19680627
• Gedebjerg A, Bjerre M, Kjaergaard AD, et al. CRP, C-Peptide, and Risk of First-Time Cardiovascular Events and Mortality in Early Type 2 Diabetes: A Danish Cohort Study. Diabetes Care, 2023. pubmed.ncbi.nlm.nih.gov/36930691
• Beigrezaei S, Yazdanpanah Z, Soltani S, et al. The addition of exercise to a weight loss diet on inflammatory markers: a systematic review and meta-analysis of controlled clinical trials. Critical Reviews in Food Science and Nutrition, 2021. pubmed.ncbi.nlm.nih.gov/34766871

Frequently Asked Questions

What is the connection between insulin resistance and inflammation?

The connection is bidirectional. Inflammation, especially from pro-inflammatory cytokines such as TNF-alpha and IL-6, blocks the intracellular signaling cascade that insulin depends on, making cells less responsive to the hormone. At the same time, insulin-resistant fat tissue, particularly visceral fat, releases more of those same cytokines, sustaining the inflammatory state. The two conditions reinforce each other through shared pathways involving NF-kappa-B and a process researchers call metaflammation.

Does inflammation cause insulin resistance?

Yes, the evidence supports this. Pro-inflammatory cytokines interfere with insulin receptor signaling by causing inhibitory phosphorylation of insulin receptor substrate-1, which blocks the downstream steps needed for glucose uptake. Population studies such as the CARDIA cohort have shown that elevated CRP independently predicts worsening insulin resistance over time, even after controlling for body fat, suggesting inflammation contributes to insulin resistance through mechanisms beyond obesity alone.

How can I tell if I have insulin resistance-related inflammation?

There is no single test that confirms the combination, but C-reactive protein is the standard accessible marker for general inflammatory status, and fasting insulin or HOMA-IR can reflect insulin sensitivity. Elevated CRP alongside fasting hyperinsulinemia or high-normal fasting glucose can suggest the two conditions are co-occurring. Because CRP is a general wellness marker rather than a diagnostic test, persistent elevations are worth discussing with a healthcare provider who can order a fuller metabolic panel and assess clinical context.

What lifestyle changes help reduce both insulin resistance and inflammation?

The same core interventions address both: reducing visceral fat through a sustained caloric deficit, increasing physical activity with a mix of aerobic exercise and resistance training, improving dietary quality with more fiber and fewer refined carbohydrates and ultra-processed foods, and prioritizing consistent sleep. These changes work upstream on both conditions because they target the visceral fat that produces inflammatory cytokines and impairs insulin signaling simultaneously.